"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
- Patient Information:
Details with Side Effects
Zemaira (alpha-proteinase inhibitor (human)) ™ is contraindicated in individuals with a known hypersensitivity to any of its components. Zemaira (alpha-proteinase inhibitor (human)) ™ is also contraindicated in individuals with a history of anaphylaxis or severe systemic response to A1-PI products. Individuals with selective IgA deficiencies who have known antibodies against IgA (anti-IgA antibodies) should not receive Zemaira (alpha-proteinase inhibitor (human)) ™, since these patients may experience severe reactions, including anaphylaxis, to IgA that may be present in Zemaira (alpha-proteinase inhibitor (human)) ™.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Zemaira Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.